Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2020-09-18

Clinical Trial Update: Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating pasireotide with or without cabergoline in patients with Cushing's disease; study terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • CABERGOLINE (CABERGOLINE)
  • Pasireotide (pasireotide)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Cushings Disease | Phase 2 | Status: TERMINATED | Results posted: 2020-09-18